Search

Displaying results 741 - 750 of 4626 in total
  1. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    Nevertheless, xylose by itself may not necessarily serve many purposes immediately - but its metabolism results in a variety of substrates that can serve important nutritional and biological purposes. … Reduction of xylose by catalytic hydrogenation produces the common food additive sweetener substitute xylitol [DB11195].

  2. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    [A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative

  3. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by … [A215127, L14897] Although effective, these compounds are rapidly metabolized by cytidine deaminase (CDA) prior to reaching systemic circulation when administered orally, necessitating intramuscular or

  4. Drug

    Simethicone

    go.drugbank.com/drugs/DB09512
    ApprovedInvestigational

    [A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]

  5. Drug

    Pralidoxime

    go.drugbank.com/drugs/DB00733
    ApprovedInvestigationalVet approved

    If given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase

  6. Drug

    Emtricitabine

    go.drugbank.com/drugs/DB00879
    ApprovedInvestigational

    is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults[L9019] or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high … [L9019] The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.[L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]

  7. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [A274853, A274858] Sibeprenlimab is a humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells. … [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]

  8. Drug

    Ranolazine

    go.drugbank.com/drugs/DB00243
    ApprovedInvestigational

    It was originally approved by the FDA in 2006.[L5440]

  9. Drug

    Sugammadex

    go.drugbank.com/drugs/DB06206
    ApprovedInvestigational

    Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015. … Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.

  10. Drug

    Coral snake (micrurus fulvius) immune globulin antivenin (equine)

    go.drugbank.com/drugs/DB13883
    Approved

    North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snake bites. … The antivenin is a refined, concentrated, and lyophilized preparation of serum globulins obtained by fractionating blood from healthy horses that have been immunized with eastern coral snake (Micrurus